what drives us

At Chimerix, we’re committed to driving the development of groundbreaking medicines designed to protect immunocompromised patients from potentially deadly viral infections.

The Need for Antiviral Protection

  • 81,000
    Number of stem cell transplants performed every year worldwide1
  • 66%
    Proportion (or percentage) of allogeneic stem cell transplant recipients who have 2 or more dsDNA viral infections2
  • 18
    Percentage of pediatric stem cell transplant patients who experience adenovirus disease in the first 100 days following transplant3
  • 50-80%
    Estimated mortality rate associated with disseminated adenovirus disease among stem cell transplant recipients if left untreated4
  • 0
    Number of approved therapies for the treatment of adenovirus5

development pipeline

About Viral Infections in Stem Cell Transplant Patients

A recent study showed that 90 percent of allogeneic stem cell transplant (also called bone marrow or hematopoietic cell transplant) recipients had at least one DNA viral infection, and 2 out of 3 stem cell recipients experienced two or more viral infections. The study also showed that infection with multiple viruses increased the risk for overall mortality.2
Our lead product candidate, brincidofovir (CMX001), has shown broad-spectrum antiviral activity against the most important DNA viruses that affect humans, including adenovirus, the virus that causes smallpox (Variola) and cytomegalovirus (CMV).

Brincidofovir has a high barrier to resistance, no myelosuppression and low risk of nephrotoxicity. Brincidofovir has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for adenovirus, smallpox and cytomegalovirus. Brincidofovir has also received Orphan Medicinal Product Designations from the European Commission for the treatment of adenovirus, the prevention of CMV disease and for the treatment of smallpox. Both oral and intravenous formulations of brincidofovir are in development.
Brincidofovir for Adenovirus
Chimerix has initiated the AdAPT (Adenovirus After Pediatric Transplantation) study, an open label, comparative trial of brincidofovir (CMX001) versus ‘usual care’. For more information on the AdAPT trial, visit clinicaltrials.gov
Brincidofovir for Smallpox
We are working with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop brincidofovir as a medical countermeasure to treat potential smallpox cases due to a bioterror event or accidental release. Brincidofovir is being developed for smallpox under the FDA’s Animal Rule.

disease areas of expertise


Adenovirus, which causes the common cold in people with healthy immune systems, can lead to life-threatening infections in immunocompromised people.4

Cytomegalovirus (CMV)

Cytomegalovirus (CMV) is a member of the herpesvirus family and remains a significant cause of viral infections in transplant recipients.

BK Virus

The majority of adults have been infected with BK virus6, which can reactivate and cause severe complications in stem cell transplant and solid organ transplant recipients, and other immunocompromised individuals. 7


Though smallpox has been officially eradicated, it remains a threat in cases of bioterror or as a potential bioterror weapon.


Noroviruses are the most common cause of acute gastroenteritis worldwide. In immunocompromised adults, norovirus infection can become chronic and persist for weeks to years.8